Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density

By / 31/07/2023

Transcenta Holding Limited announces that it has received approval from China Center for Drug Evaluation to initiate Phase II clinical trial of TST002.